Amy May Lin Quek , Suqing Wang , Ooiean Teng , Bhuvaneshwari Shunmuganathan , Bernadette Guek Cheng Er , Nor Fa'izah Binte Mahmud , Isabel Xue Qi Ng , Rashi Gupta , Isabelle Siang Ling Tan , Nikki YJ Tan , Xinlei Qian , Kiren Purushotorman , Hock Luen Teoh , Kay Wei Ping Ng , Yihui Goh , Derek Tuck Loong Soon , Sen Hee Tay , Gim Gee Teng , Margaret Ma , Nisha Suyien Chandran , Raymond Chee Seong Seet
{"title":"Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals","authors":"Amy May Lin Quek , Suqing Wang , Ooiean Teng , Bhuvaneshwari Shunmuganathan , Bernadette Guek Cheng Er , Nor Fa'izah Binte Mahmud , Isabel Xue Qi Ng , Rashi Gupta , Isabelle Siang Ling Tan , Nikki YJ Tan , Xinlei Qian , Kiren Purushotorman , Hock Luen Teoh , Kay Wei Ping Ng , Yihui Goh , Derek Tuck Loong Soon , Sen Hee Tay , Gim Gee Teng , Margaret Ma , Nisha Suyien Chandran , Raymond Chee Seong Seet","doi":"10.1016/j.jinf.2024.106238","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Immunity to SARS-CoV-2 vaccination and infection differs considerably among individuals. We investigate the critical pathways that influence vaccine-induced cross-variant serological immunity among individuals at high-risk of COVID-19 complications.</p></div><div><h3>Methods</h3><p>Neutralizing antibodies to the wild-type SARS-CoV-2 virus and its variants (Beta, Gamma, Delta and Omicron) were analyzed in patients with autoimmune diseases, chronic comorbidities (multimorbidity), and healthy controls. Antibody levels were assessed at baseline and at different intervals up to 12 months following primary and booster vaccination with either BNT162b2 or mRNA-1273. Immunity induced by vaccination with and without infection (hybrid immunity) was compared with that of unvaccinated individuals with recent SARS-CoV-2 infection. Plasma cytokines were analyzed to investigate variations in antibody production following vaccination.</p></div><div><h3>Results</h3><p>Patients with autoimmune diseases (n = 137) produced lesser antibodies to the wild-type SARS-CoV-2 virus and its variants compared with those in the multimorbidity (n = 153) and healthy groups (n = 229); antibody levels were significantly lower in patients with neuromyelitis optica and those on prednisolone, mycophenolate or rituximab treatment. Multivariate logistic regression analysis identified neuromyelitis optica (odds ratio 8.20, 95% CI 1.68–39.9) and mycophenolate (13.69, 3.78–49.5) as significant predictors of a poorer antibody response to vaccination (i.e, neutralizing antibody <40%). Infected participants exhibited antibody levels that were 28.7% higher (95% CI 24.7–32.7) compared to non-infected participants six months after receiving a booster vaccination. Individuals infected during the Delta outbreak generated cross-protective neutralizing antibodies against the Omicron variant in quantities comparable to those observed after infection with the Omicron variant itself. In contrast, unvaccinated individuals recently infected with the wild-type (n = 2390) consistently displayed lower levels of neutralizing antibodies against both the wild-type virus and other variants. Pathway analyses suggested an inverse relationship between baseline T cell subsets and antibody production following vaccination.</p></div><div><h3>Conclusion</h3><p>Hybrid immunity confers a robust protection against COVID-19 among immunocompromised individuals.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106238"},"PeriodicalIF":11.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001725/pdfft?md5=4ed425af644f43419f203a14862cdc88&pid=1-s2.0-S0163445324001725-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163445324001725","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Immunity to SARS-CoV-2 vaccination and infection differs considerably among individuals. We investigate the critical pathways that influence vaccine-induced cross-variant serological immunity among individuals at high-risk of COVID-19 complications.
Methods
Neutralizing antibodies to the wild-type SARS-CoV-2 virus and its variants (Beta, Gamma, Delta and Omicron) were analyzed in patients with autoimmune diseases, chronic comorbidities (multimorbidity), and healthy controls. Antibody levels were assessed at baseline and at different intervals up to 12 months following primary and booster vaccination with either BNT162b2 or mRNA-1273. Immunity induced by vaccination with and without infection (hybrid immunity) was compared with that of unvaccinated individuals with recent SARS-CoV-2 infection. Plasma cytokines were analyzed to investigate variations in antibody production following vaccination.
Results
Patients with autoimmune diseases (n = 137) produced lesser antibodies to the wild-type SARS-CoV-2 virus and its variants compared with those in the multimorbidity (n = 153) and healthy groups (n = 229); antibody levels were significantly lower in patients with neuromyelitis optica and those on prednisolone, mycophenolate or rituximab treatment. Multivariate logistic regression analysis identified neuromyelitis optica (odds ratio 8.20, 95% CI 1.68–39.9) and mycophenolate (13.69, 3.78–49.5) as significant predictors of a poorer antibody response to vaccination (i.e, neutralizing antibody <40%). Infected participants exhibited antibody levels that were 28.7% higher (95% CI 24.7–32.7) compared to non-infected participants six months after receiving a booster vaccination. Individuals infected during the Delta outbreak generated cross-protective neutralizing antibodies against the Omicron variant in quantities comparable to those observed after infection with the Omicron variant itself. In contrast, unvaccinated individuals recently infected with the wild-type (n = 2390) consistently displayed lower levels of neutralizing antibodies against both the wild-type virus and other variants. Pathway analyses suggested an inverse relationship between baseline T cell subsets and antibody production following vaccination.
Conclusion
Hybrid immunity confers a robust protection against COVID-19 among immunocompromised individuals.
期刊介绍：
The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection.
Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
